Biocon Integrates Biologics Arm in $5.5 Billion Share Swap
Biocon announces full integration of its biosimilars unit, Biocon Biologics, in a deal valuing it at $5.5 billion. The move aims to create a unified powerhouse in diabetes, oncology, and immunology markets. Read more.